LIVIVO - Search results -

Search results

Result 1 - 10 of total 44

Search options

Article ; Online: Inequities in Indirect Cost Rates Between Historically Black Colleges and Universities and Other Institutions.

Hauschildt, Katrina E / Messersmith, Julie / Iwashyna, Theodore J

Academic medicine : journal of the Association of American Medical Colleges

2024

Abstract: Purpose: Federal research grants provide support for the indirect costs (IDCs) of research infrastructure that are not specific to particular research projects but are nonetheless essential to enable research. Institutions independently negotiate IDC ... ...

Abstract	Purpose: Federal research grants provide support for the indirect costs (IDCs) of research infrastructure that are not specific to particular research projects but are nonetheless essential to enable research. Institutions independently negotiate IDC rates. The authors sought to identify whether inequities exist in negotiated IDC rates between historically Black colleges and universities (HBCUs) and other universities (non-HBCUs). Method: In 2023, the authors analyzed mean negotiated IDC rates between the top 20 HBCUs (in fiscal year [FY] 2021 research expenditures) and 3 non-HBCU comparison groups: the top 40 non-HBCUs in FY 2021 research expenditures, metropolitan statistical area (MSA)-matched non-HBCUs (among the top 200 institutions by FY 2021 research expenditures), and FY 2021 research expenditure-matched non-HBCUs. Results: The authors found that the top 20 HBCUs' mean IDC rates (50.0%) were, after adjustment, 8.5 percentage points (95% confidence interval [CI] 5.7, 11.2) lower than those of the top 40 non-HBCUs (58.5%). The mean IDC rates of top HBCUs (n = 14, 48.4%) were, after adjustment, 6.3 percentage points (95% CI 3.1, 9.4) lower than those of MSA-matched non-HBCUs (n = 23, 55.3%). There was no statistically significant difference in the mean IDC rates between the top 20 HBCUs (50.0%) and expenditure-matched non-HBCUs (n = 31; 48.2%). Conclusions: Inequities in negotiated IDC rates between top HBCUs and non-HBCUs likely both reflect and may contribute to the persistence of institution-level inequities in federally funded research. Proactive investments in HBCUs' research infrastructures are likely needed to ameliorate these funding inequities and support the role of HBCUs in providing opportunity for underrepresented groups in biomedical sciences.
Language	English
Publishing date	2024-03-25
Publishing country	United States
Document type	Journal Article
ZDB-ID	96192-9
ISSN	1938-808X ; 1040-2446
ISSN (online)	1938-808X
ISSN	1040-2446
DOI	10.1097/ACM.0000000000005717
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 112: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: 'It opened my eyes, my ears, and my heart': Codesigning a substance use disorder treatment programme.

Bosak, Julie / Drainoni, Mari-Lynn / Bryer, Cheri / Goodman, Daisy / Messersmith, Lisa / Declercq, Eugene

Health expectations : an international journal of public participation in health care and health policy

2023

Abstract: Background: Pregnant and parenting women have low engagement and poor retention in substance use disorder (SUD) treatment. The aim of this study was to analyse the implementation of an adapted experience-based codesign (EBCD) process involving SUD ... ...

Abstract	Background: Pregnant and parenting women have low engagement and poor retention in substance use disorder (SUD) treatment. The aim of this study was to analyse the implementation of an adapted experience-based codesign (EBCD) process involving SUD treatment staff and pregnant or parenting women with lived experience (WWLE) of SUD to launch a residential treatment service where women could coreside with their children and receive long term comprehensive treatment for dual diagnosis of SUD and mental illness. Methods: A process evaluation was conducted utilising five data sources: two sets of semistructured interviews with WWLE and SUD treatment staff, ethnographic observation and transcripts from group events, and meeting minutes. Based on the Integrated Promoting Action on Research in Health Services framework constructs (context, recipients, facilitation, innovation) researchers applied thematic analysis to determine main themes within each construct. Results: The full sample across the implementation totalled 34 individuals (WWLE = 13 and SUD staff = 21). The EBCD process engaged both cohorts and supported group cohesion and collaborative brainstorming. WWLE felt respected, emotionally safe to share, and empowered by participation. A cohesive, multidisciplinary codesign planning group, inclusive of WWLE, supported a more equitable codesign process. The need for a virtual platform due to the COVID-19 pandemic impeded human connection and relationship building. The complex environment of residential regulations and uncertainties during start-up phase of an organisation presented implementation challenges. Conclusion: These results highlight the feasibility of, and challenges to, effectively engaging WWLE in a codesign process. The findings also demonstrated a positive influence on WWLE's feelings of empowerment. Identified themes reinforce the purposeful components within EBCD that enhance participation, along with new insights to inform successful codesign with a vulnerable population. The author's team included a WWLE who collaborated throughout the full scope of the research process, enriching the overall research and ensuring the authenticity of the presentation of women in recovery's perspective. Utilising the codesign approach to design and implement new services should improve health equity by enhancing patient engagement and retention in care. Patient contribution: Parenting WWLE of residential SUD treatment were involved in the full scope of the research process and the implementation being evaluated. For the actual codesign work WWLE were key members of the codesign planning team that met weekly throughout the implementation to plan, implement, problem solve and adapt the process over an 18 month timeframe. As is appropriate for codesign the actual ongoing workgroup participants had average 50% WWLE participation. For the research team, this research is a culmination of the lead author's doctoral dissertation. One member of the five-person dissertation committee was a recovery coach and a WWLE. She was an active participant across the entire research process overseeing and influencing the research design, conduct of the study, analysis, interpretation of findings and approval of the final manuscript. The findings were member checked with the larger codesign planning group that had additional WWLE members.
Language	English
Publishing date	2023-11-03
Publishing country	England
Document type	Journal Article
ZDB-ID	2119434-8
ISSN	1369-7625 ; 1369-6513
ISSN (online)	1369-7625
ISSN	1369-6513
DOI	10.1111/hex.13908
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5896: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Emergency seed funding for COVID-19 research: lessons from Johns Hopkins University.

Messersmith, Julie / Stoddart-Osumah, Chasmine / Lennon, Marc / Wirtz, Denis

The Journal of clinical investigation

2020 Volume 131, Issue 1

MeSH term(s)	Biomedical Research/economics ; COVID-19/economics ; Capital Financing ; Financing, Government ; Humans ; SARS-CoV-2 ; Universities/economics
Keywords	covid19
Language	English
Publishing date	2020-11-20
Publishing country	United States
Document type	Journal Article
ZDB-ID	3067-3
ISSN	1558-8238 ; 0021-9738
ISSN (online)	1558-8238
ISSN	0021-9738
DOI	10.1172/JCI145615
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.184: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Emergency seed funding for COVID-19 research: lessons from Johns Hopkins University

Messersmith, Julie / Stoddart-Osumah, Chasmine / Lennon, Marc / Wirtz, Denis

J. clin. invest

Abstract: Seed grant programs are an efficient mechanism for universities to invest in high-risk ideas, incite collaborative research, support early career faculty, and direct faculty towards a specific goal. At the outset of the COVID-19 pandemic, Johns Hopkins ... ...

Abstract	Seed grant programs are an efficient mechanism for universities to invest in high-risk ideas, incite collaborative research, support early career faculty, and direct faculty towards a specific goal. At the outset of the COVID-19 pandemic, Johns Hopkins leadership quickly mobilized to support research teams as they pivoted to gather preliminary data and seek solutions to save lives. Here we discuss key lessons learned from the program.
Keywords	covid19
Publisher	WHO
Document type	Article
Note	WHO #Covidence: #917844
Database	COVID19

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article: Cabozantinib sensitizes microsatellite stable colorectal cancer to immune checkpoint blockade by immune modulation in human immune system mouse models.

Lang, Julie / Leal, Alexis D / Marín-Jiménez, Juan A / Hartman, Sarah J / Shulman, Jeremy / Navarro, Natalie M / Lewis, Matthew S / Capasso, Anna / Bagby, Stacey M / Yacob, Bethlehem W / MacBeth, Morgan / Freed, Brian M / Eckhardt, S Gail / Jordan, Kimberly / Blatchford, Patrick J / Pelanda, Roberta / Lieu, Christopher H / Messersmith, Wells A / Pitts, Todd M

Frontiers in oncology

2022 Volume 12, Page(s) 877635

Abstract: Immune checkpoint inhibitors have been found to be effective in metastatic MSI-high colorectal cancers (CRC), however, have no efficacy in microsatellite stable (MSS) cancers, which comprise the majority of mCRC cases. Cabozantinib is a small molecule ... ...

Abstract	Immune checkpoint inhibitors have been found to be effective in metastatic MSI-high colorectal cancers (CRC), however, have no efficacy in microsatellite stable (MSS) cancers, which comprise the majority of mCRC cases. Cabozantinib is a small molecule multi-tyrosine kinase inhibitor that is FDA approved in advanced renal cell, medullary thyroid, and hepatocellular carcinoma. Using Human Immune System (HIS) mice, we tested the ability of cabozantinib to prime MSS-CRC tumors to enhance the potency of immune checkpoint inhibitor nivolumab. In four independent experiments, we implanted distinct MSS-CRC patient-derived xenografts (PDXs) into the flanks of humanized BALB/c-Rag2
Language	English
Publishing date	2022-11-07
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2649216-7
ISSN	2234-943X
ISSN	2234-943X
DOI	10.3389/fonc.2022.877635
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Benchmarks for Academic Oncology Faculty.

Anthony, Lowell / Atweh, George / Bhatia, Ravi / Carey, Lisa A / Chang, Jenny C / Edelman, Martin J / Kantoff, Philip W / Markham, Merry Jennifer / Messersmith, Wells / Nelson, Edward L / Oettel, Kurt / O'Regan, Ruth / Verschraegen, Claire F / Vose, Julie M

JCO oncology practice

2020 Volume 17, Issue 3, Page(s) e440–e444

Abstract: The role of clinical researchers is vital to cancer progress. The teaching, research, and leadership roles that academic oncologists hold need to be accounted for and appropriately compensated. National metrics are currently inexistent, but are necessary ...

Abstract	The role of clinical researchers is vital to cancer progress. The teaching, research, and leadership roles that academic oncologists hold need to be accounted for and appropriately compensated. National metrics are currently inexistent, but are necessary to move the oncology research field forward. Clinical research and routine clinical care must be harmoniously integrated without competing. This article reviews the national landscape of clinical cancer research and proposes a call for action.
MeSH term(s)	Benchmarking ; Faculty, Medical ; Humans ; Leadership ; Medical Oncology ; Research Personnel
Language	English
Publishing date	2020-09-30
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	3028198-2
ISSN	2688-1535 ; 2688-1527
ISSN (online)	2688-1535
ISSN	2688-1527
DOI	10.1200/OP.20.00020
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 7198: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A Phase II Study Investigating Cabozantinib in Patients with Refractory Metastatic Colorectal Cancer (AGICC 17CRC01).

Scott, Aaron J / Basu Mallick, Atrayee / Dotan, Efrat / Cohen, Steven J / Gold, Philip J / Hochster, Howard S / Subramaniam, Somasundaram / Barzi, Afsaneh / Watts, George S / Blatchford, Patrick J / Messersmith, Wells A

Cancer research communications

2022 Volume 2, Issue 10, Page(s) 1188–1196

Abstract: ... PFS) was conducted in eight cancer centers across the United States between May 2018 and July 2020 ...

Abstract	Purpose: Multi-tyrosine kinase inhibitors (TKI) have shown clinical activity in patients with metastatic colorectal cancer. Cabozantinib, a multi-TKI, exhibited potent antitumor activity superior to regorafenib in preclinical colorectal cancer patient-derived tumor xenograft models. This phase II study aimed to investigate cabozantinib, a multi-TKI, in patients with refractory, metastatic colorectal cancer (mCRC). Experimental design: A nonrandomized, two-stage, phase II clinical trial evaluating 12-week progression-free survival (PFS) was conducted in eight cancer centers across the United States between May 2018 and July 2020. Results: A total of 44 patients were enrolled between May 2018 and May 2019, 40 of which were response evaluable. Of the total 769 reported adverse events (AE), 93 (12%) were ≥ grade 3. Five grade 5 AEs were reported of which four were unrelated to study drug and one was reported as possibly related due to bowel perforation. Eighteen patients (45%) achieved 12-week PFS with stable disease or better (confidence interval, 0.29-0.62; Conclusions: This phase II study demonstrated clinical activity of cabozantinib in heavily pretreated, patients with refractory mCRC, and supports further investigation. Significance: Targeting angiogenesis through VEGF axis blockade provides incremental survival benefit in patients with mCRC. The hepatocyte growth factor/MET signal transduction pathway has been observed as a mechanism for acquired resistance. Dual inhibition of VEGF plus MET is an attractive therapeutic strategy. This phase II trial demonstrated clinical activity with cabozantinib, a multi-TKI targeting VEGFR2 and MET, in patients with refractory, mCRC.
MeSH term(s)	Humans ; Colorectal Neoplasms/drug therapy ; Pyridines/adverse effects ; Vascular Endothelial Growth Factor A/therapeutic use ; Prospective Studies
Chemical Substances	cabozantinib (1C39JW444G) ; Pyridines ; regorafenib (24T2A1DOYB) ; Vascular Endothelial Growth Factor A
Language	English
Publishing date	2022-10-14
Publishing country	United States
Document type	Clinical Trial ; Clinical Trial, Phase II ; Journal Article ; Research Support, Non-U.S. Gov't
ISSN	2767-9764
ISSN (online)	2767-9764
DOI	10.1158/2767-9764.CRC-22-0169
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes.

Marín-Jiménez, Juan A / Capasso, Anna / Lewis, Matthew S / Bagby, Stacey M / Hartman, Sarah J / Shulman, Jeremy / Navarro, Natalie M / Yu, Hui / Rivard, Chris J / Wang, Xiaoguang / Barkow, Jessica C / Geng, Degui / Kar, Adwitiya / Yingst, Ashley / Tufa, Dejene M / Dolan, James T / Blatchford, Patrick J / Freed, Brian M / Torres, Raul M /

Davila, Eduardo / Slansky, Jill E / Pelanda, Roberta / Eckhardt, S Gail / Messersmith, Wells A / Diamond, Jennifer R / Lieu, Christopher H / Verneris, Michael R / Wang, Jing H / Kiseljak-Vassiliades, Katja / Pitts, Todd M / Lang, Julie

Frontiers in immunology

2021 Volume 12, Page(s) 607282

Abstract: Over the past decade, immunotherapies have revolutionized the treatment of cancer. Although the success of immunotherapy is remarkable, it is still limited to a subset of patients. More than 1500 clinical trials are currently ongoing with a goal of ... ...

Abstract	Over the past decade, immunotherapies have revolutionized the treatment of cancer. Although the success of immunotherapy is remarkable, it is still limited to a subset of patients. More than 1500 clinical trials are currently ongoing with a goal of improving the efficacy of immunotherapy through co-administration of other agents. Preclinical, small-animal models are strongly desired to increase the pace of scientific discovery, while reducing the cost of combination drug testing in humans. Human immune system (HIS) mice are highly immune-deficient mouse recipients rtpeconstituted with human hematopoietic stem cells. These HIS-mice are capable of growing human tumor cell lines and patient-derived tumor xenografts. This model allows rapid testing of multiple, immune-related therapeutics for tumors originating from unique clinical samples. Using a cord blood-derived HIS-BALB/c-Rag2
MeSH term(s)	Animals ; Chimerism ; Disease Models, Animal ; Hematopoietic Stem Cell Transplantation ; Heterografts ; Humans ; Immune System ; Immunotherapy/adverse effects ; Immunotherapy/methods ; Lymphocyte Subsets/immunology ; Lymphocyte Subsets/metabolism ; Lymphoid Tissue/immunology ; Lymphoid Tissue/metabolism ; Mice ; Mice, Inbred NOD ; Mice, Knockout ; Mice, SCID ; Neoplasms/etiology ; Neoplasms/immunology ; Neoplasms/therapy ; Phenotype ; Xenograft Model Antitumor Assays
Language	English
Publishing date	2021-03-29
Publishing country	Switzerland
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
ZDB-ID	2606827-8
ISSN	1664-3224 ; 1664-3224
ISSN (online)	1664-3224
ISSN	1664-3224
DOI	10.3389/fimmu.2021.607282
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: High levels of used syringe use and unsafe sex among people who inject drugs in Kumasi, Ghana: an urgent call for a comprehensive harm reduction approach.

Messersmith, Lisa J / Adjei, Rose / Beard, Jennifer / Bazzi, Angela R / Earlywine, Joel J / Darko, Edwin / Agyarko-Poku, Thomas / Asafo, Mabel Kissiwah / Bempah, Sherry Adoma / Adu-Sarkodie, Yaw

Harm reduction journal

2021 Volume 18, Issue 1, Page(s) 62

Abstract: ... population in order to inform much-needed harm reduction interventions.: Methods: From April to July 2018 ...

Abstract	Background: Drug use is a growing concern in Ghana. People who inject drugs (PWID) are highly vulnerable to HIV and other infectious diseases. Ghana's National Strategic Plan for HIV/AIDS 2016-2020 identifies PWID as a key population, but efforts to address the needs of PWID have lagged behind those targeting sex workers and men who have sex with men. Lack of information about PWID is a critical barrier to implementing effective HIV prevention and treatment. We aimed to learn more about the vulnerability of the PWID population in order to inform much-needed harm reduction interventions. Methods: From April to July 2018, we conducted a mixed methods study in Kumasi, Ghana, to identify all major drug using locations, count the numbers of PWID to obtain rough population size estimations, and administer anonymous surveys to 221 PWID regarding drug use and sexual behavior. We also tested for HIV, HCV, and HBV from syringes used by survey participants. Results: Key informants identified five major drug using locations and estimated the total PWID population size to be between 600 and 2000. Enumerators counted between 35 and 61 individuals present at each of the five bases. Sharing syringes and reusing discarded syringes are common practices. Over half of survey participants (59%) reported past-month syringe sharing (34% used a used syringe and 52% gave away a used syringe). Individuals with higher injection frequency (≥ 21 times weekly) and who injected with four or more people had higher odds of syringe sharing. Of the survey participants reporting sex in the last month (23%), most reported having one partner, but only 12% used condoms. Nearly all women (11/13) reported exchanging sex for drugs and 6/13 reported exchanging sex for money in the last six months. Fifteen percent of participants (all men) reported paying for sex using drugs or money. Of the used syringes, prevalence estimates were 3% (HIV), 2% (HCV), and 9% (HBV). Conclusions: Our findings confirm the urgent need to implement harm reduction interventions targeting PWID and to build a strong and enabling legal and policy environment in Ghana to support these efforts.
MeSH term(s)	Female ; Ghana/epidemiology ; HIV Infections/epidemiology ; HIV Infections/prevention & control ; Harm Reduction ; Homosexuality, Male ; Humans ; Male ; Needle Sharing ; Pharmaceutical Preparations ; Risk-Taking ; Sexual and Gender Minorities ; Substance Abuse, Intravenous/epidemiology ; Syringes ; Unsafe Sex
Chemical Substances	Pharmaceutical Preparations
Language	English
Publishing date	2021-06-10
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2146691-9
ISSN	1477-7517 ; 1477-7517
ISSN (online)	1477-7517
ISSN	1477-7517
DOI	10.1186/s12954-021-00510-7
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Development of an Adrenocortical Cancer Humanized Mouse Model to Characterize Anti-PD1 Effects on Tumor Microenvironment.

Lang, Julie / Capasso, Anna / Jordan, Kimberly R / French, Jena D / Kar, Adwitiya / Bagby, Stacey M / Barbee, Jacob / Yacob, Betelehem W / Head, Lia S / Tompkins, Kenneth D / Freed, Brian M / Somerset, Hilary / Clark, Toshimasa J / Pitts, Todd M / Messersmith, Wells A / Eckhardt, S Gail / Wierman, Margaret E / Leong, Stephen / Kiseljak-Vassiliades, Katja

The Journal of clinical endocrinology and metabolism

2019 Volume 105, Issue 1

Abstract: Context: Although the development of immune checkpoint inhibitors has transformed treatment strategies of several human malignancies, research models to study immunotherapy in adrenocortical carcinoma (ACC) are lacking.: Objective: To explore the ... ...

Abstract	Context: Although the development of immune checkpoint inhibitors has transformed treatment strategies of several human malignancies, research models to study immunotherapy in adrenocortical carcinoma (ACC) are lacking. Objective: To explore the effect of anti-PD1 immunotherapy on the alteration of the immune milieu in ACC in a newly generated preclinical model and correlate with the response of the matched patient. Design, setting, and intervention: To characterize the CU-ACC2-M2B patient-derived xenograft in a humanized mouse model, evaluate the effect of a PD-1 inhibitor therapy, and compare it with the CU-ACC2 patient with metastatic disease. Results: Characterization of the CU-ACC2-humanized cord blood-BALB/c-Rag2nullIl2rγnullSirpaNOD model confirmed ACC origin and match with the original human tumor. Treatment of the mice with pembrolizumab demonstrated significant tumor growth inhibition (60%) compared with controls, which correlated with increased tumor infiltrating lymphocyte activity, with an increase of human CD8+ T cells (P < 0.05), HLA-DR+ T cells (P < 0.05) as well as Granzyme B+ CD8+ T cells (<0.001). In parallel, treatment of the CU-ACC2 patient, who had progressive disease, demonstrated a partial response with 79% to 100% reduction in the size of target lesions, and no new sites of metastasis. Pretreatment analysis of the patient's metastatic liver lesion demonstrated abundant intratumoral CD8+ T cells by immunohistochemistry. Conclusions: Our study reports the first humanized ACC patient-derived xenograft mouse model, which may be useful to define mechanisms and biomarkers of response and resistance to immune-based therapies, to ultimately provide more personalized care for patients with ACC.
MeSH term(s)	Adrenal Cortex Neoplasms/drug therapy ; Adrenal Cortex Neoplasms/immunology ; Adrenal Cortex Neoplasms/pathology ; Adrenocortical Carcinoma/drug therapy ; Adrenocortical Carcinoma/immunology ; Adrenocortical Carcinoma/pathology ; Animals ; Antibodies, Monoclonal, Humanized/pharmacology ; Antineoplastic Agents, Immunological/pharmacology ; Apoptosis ; Cell Proliferation ; Disease Models, Animal ; Female ; Humans ; Immunotherapy ; Lymphocytes, Tumor-Infiltrating/drug effects ; Lymphocytes, Tumor-Infiltrating/immunology ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/immunology ; Tumor Cells, Cultured ; Tumor Microenvironment/drug effects ; Tumor Microenvironment/immunology ; Xenograft Model Antitumor Assays
Chemical Substances	Antibodies, Monoclonal, Humanized ; Antineoplastic Agents, Immunological ; PDCD1 protein, human ; Programmed Cell Death 1 Receptor ; pembrolizumab (DPT0O3T46P)
Language	English
Publishing date	2019-09-05
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
ZDB-ID	3029-6
ISSN	1945-7197 ; 0021-972X
ISSN (online)	1945-7197
ISSN	0021-972X
DOI	10.1210/clinem/dgz014
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.134: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito